2020 Form 10-K Financial Statement

#000162828021003277 Filed on February 25, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $366.0K $90.00K $244.6K
YoY Change 49.61% 12.5% -35.34%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0%
Gross Profit $90.00K $244.6K
YoY Change 12.5% -211.64%
Gross Profit Margin 100.0% 100.0%
Selling, General & Admin $8.217M $1.520M $5.761M
YoY Change 42.63% -9.52% -28.04%
% of Gross Profit 1688.89% 2354.92%
Research & Development $11.24M $2.860M $11.16M
YoY Change 0.66% 14.4% 36.72%
% of Gross Profit 3177.78% 4562.87%
Depreciation & Amortization $466.0K $360.0K $494.2K
YoY Change -5.71% 125.0% -42.5%
% of Gross Profit 400.0% 202.03%
Operating Expenses $19.45M $4.380M $16.92M
YoY Change 14.94% 4.78% -2.92%
Operating Profit -$19.09M -$4.290M -$16.68M
YoY Change 14.43% 4.63% -2.2%
Interest Expense $2.000K $50.00K $0.00
YoY Change -54.55% -100.0%
% of Operating Profit
Other Income/Expense, Net -$221.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$19.31M -$4.240M -$16.41M
YoY Change 17.67% 1.92% -0.3%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.31M -$4.240M -$16.41M
YoY Change 17.62% 1.92% -0.29%
Net Earnings / Revenue -5275.24% -4711.11% -6709.74%
Basic Earnings Per Share -$1.08
Diluted Earnings Per Share -$1.08 -$485.7K -$2.749M
COMMON SHARES
Basic Shares Outstanding 20.88M shares 7.742M shares 5.974M shares
Diluted Shares Outstanding 20.88M shares

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $131.0M $10.20M $10.20M
YoY Change 1184.31% -11.3% -11.3%
Cash & Equivalents $131.0M $10.20M $10.20M
Short-Term Investments
Other Short-Term Assets $2.100M $1.000M $1.000M
YoY Change 110.0% -9.09% -9.09%
Inventory
Prepaid Expenses $955.0K
Receivables $300.0K $203.5K $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $133.4M $11.35M $11.40M
YoY Change 1070.18% -11.06% -10.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000M $877.8K $1.600M
YoY Change -37.5% -32.7% 23.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $157.6K $200.0K
YoY Change 100.0% 53.29% 100.0%
Total Long-Term Assets $1.300M $1.733M $1.700M
YoY Change -23.53% 23.14% 21.43%
TOTAL ASSETS
Total Short-Term Assets $133.4M $11.35M $11.40M
Total Long-Term Assets $1.300M $1.733M $1.700M
Total Assets $134.7M $13.09M $13.10M
YoY Change 928.24% -7.66% -7.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $656.3K $700.0K
YoY Change 100.0% -1.28% 0.0%
Accrued Expenses $4.200M $3.260M $3.700M
YoY Change 13.51% 83.99% 164.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.100M $4.782M $4.800M
YoY Change 27.08% 63.57% 65.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $128.4K $1.000M
YoY Change -50.0% 205.64% -16.67%
Total Long-Term Liabilities $500.0K $128.4K $1.000M
YoY Change -50.0% 205.64% -16.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.100M $4.782M $4.800M
Total Long-Term Liabilities $500.0K $128.4K $1.000M
Total Liabilities $6.600M $5.775M $5.800M
YoY Change 13.79% 41.26% 41.46%
SHAREHOLDERS EQUITY
Retained Earnings -$208.9M
YoY Change 8.69%
Common Stock $8.312K
YoY Change 7.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.2M $7.312M $7.300M
YoY Change
Total Liabilities & Shareholders Equity $134.7M $13.09M $13.10M
YoY Change 928.24% -7.66% -7.75%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$19.31M -$4.240M -$16.41M
YoY Change 17.62% 1.92% -0.29%
Depreciation, Depletion And Amortization $466.0K $360.0K $494.2K
YoY Change -5.71% 125.0% -42.5%
Cash From Operating Activities -$16.32M -$3.280M -$13.27M
YoY Change 22.97% -9.14% 0.52%
INVESTING ACTIVITIES
Capital Expenditures $211.0K $0.00 $67.62K
YoY Change 212.03% 1225.92%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$211.0K $0.00 -$67.62K
YoY Change 212.03% -396.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $112.3M $8.818M
YoY Change 1173.56% -25.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $137.3M 4.440M $12.08M
YoY Change 1036.94% -26.37%
NET CHANGE
Cash From Operating Activities -$16.32M -3.280M -$13.27M
Cash From Investing Activities -$211.0K 0.000 -$67.62K
Cash From Financing Activities $137.3M 4.440M $12.08M
Net Change In Cash $120.8M 1.160M -$1.258M
YoY Change -9702.64% -132.13% -138.97%
FREE CASH FLOW
Cash From Operating Activities -$16.32M -$3.280M -$13.27M
Capital Expenditures $211.0K $0.00 $67.62K
Free Cash Flow -$16.53M -$3.280M -$13.34M
YoY Change 23.93% -9.14% 0.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001213037
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-35558
CY2020 dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2020 dei City Area Code
CityAreaCode
858
CY2020 dei Local Phone Number
LocalPhoneNumber
952-7570
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
103720151 USD
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37052129 shares
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130980681 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10195292 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
320458 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
203480 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2055321 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
954957 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
133356460 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
11353729 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
623694 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877823 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343001 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697418 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
404232 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
157576 USD
CY2020Q4 us-gaap Assets
Assets
134727387 USD
CY2019Q4 us-gaap Assets
Assets
13086546 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1366008 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
656304 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3850763 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3260061 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
860206 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
865379 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6118977 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
60 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4781744 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
284971 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4127 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9291 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860963 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
156266 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
128368 USD
CY2020Q4 us-gaap Liabilities
Liabilities
6569505 USD
CY2019Q4 us-gaap Liabilities
Liabilities
5775202 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
716 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36780805 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36780805 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8593633 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8593633 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3678 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
8312 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
361820025 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
217172528 USD
CY2020Q4 trov Servicereceivable
Servicereceivable
2171258 USD
CY2019Q4 trov Servicereceivable
Servicereceivable
971673 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-231495279 USD
CY2020 us-gaap Revenues
Revenues
365993 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208897883 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128157882 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7311344 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134727387 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13086546 USD
CY2019 us-gaap Revenues
Revenues
244632 USD
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11235396 USD
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11162236 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8216471 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5760890 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
19451867 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
16923126 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19085874 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-16678494 USD
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
89809 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
234169 USD
CY2020 us-gaap Interest Expense
InterestExpense
1519 USD
CY2019 us-gaap Interest Expense
InterestExpense
0 USD
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-28244 USD
CY2019 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1978 USD
CY2020 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-280844 USD
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
28188 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19306672 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-16414159 USD
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24240 USD
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24240 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22597396 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16706668 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.80
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20874665 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5973906 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10084192 USD
CY2019 trov Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-8817772 USD
CY2019 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-40000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
884942 USD
CY2019 trov Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3299510 USD
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2019 trov Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock
BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
0 USD
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24240 USD
CY2019 trov Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
703327 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-16414159 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7311344 USD
CY2020 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
112299949 USD
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-7500 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1764804 USD
CY2020 trov Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
24871586 USD
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24240 USD
CY2020 trov Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
1100415 USD
CY2020 trov Adjustments To Additional Paid In Capital Common Stock Par Value Adjustment
AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment
0 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148196 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19306672 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128157882 USD
CY2020 trov Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
7507123 USD
CY2020 trov Warrants Fair Value
WarrantsFairValue
370666 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19306672 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-16414159 USD
CY2020 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
34169 USD
CY2019 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
466009 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
494232 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1764804 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
884943 USD
CY2020 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-280844 USD
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
28188 USD
CY2020 trov Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
1100415 USD
CY2019 trov Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
703327 USD
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
246656 USD
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
54778 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
116978 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
35725 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1100364 USD
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-115459 USD
CY2020 trov Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-320248 USD
CY2019 trov Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-302491 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1276166 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1455336 USD
CY2020 trov Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-856845 USD
CY2019 trov Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-776806 USD
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
69898 USD
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
86368 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16314962 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13267500 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
211880 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67622 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-211880 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67622 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
112299949 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8817772 USD
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7500 USD
CY2019 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-40000 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24871586 USD
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3299509 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
148196 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
305000 USD
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
305000 USD
CY2019 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
137312231 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12077281 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
120785389 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1257841 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10195292 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11453133 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130980681 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10195292 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
CY2020 trov Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
24240 USD
CY2019 trov Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
24240 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131000000.0 USD
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.</span></div>
CY2020Q4 trov Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
1683195 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11235396 USD
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.</span></div>
CY2020 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.
CY2019 us-gaap Depreciation
Depreciation
494232 USD
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9807474 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11617078 shares
CY2020 us-gaap Depreciation
Depreciation
466009 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3627719 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3482116 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3004025 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2604293 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
623694 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877823 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1523321 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1003383 USD
CY2020Q4 trov Accrued Preferred Stock Dividend
AccruedPreferredStockDividend
389495 USD
CY2019Q4 trov Accrued Preferred Stock Dividend
AccruedPreferredStockDividend
365255 USD
CY2020Q4 trov Accrued Clinical Trial
AccruedClinicalTrial
1557134 USD
CY2019Q4 trov Accrued Clinical Trial
AccruedClinicalTrial
1504660 USD
CY2020Q4 trov Accruedresearchagreements
Accruedresearchagreements
66593 USD
CY2019Q4 trov Accruedresearchagreements
Accruedresearchagreements
181408 USD
CY2020Q4 trov Accrueddirectorfees
Accrueddirectorfees
92500 USD
CY2019Q4 trov Accrueddirectorfees
Accrueddirectorfees
67500 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
38180 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
21000 USD
CY2020Q4 trov Patentlicenseandotherfeespayable
Patentlicenseandotherfeespayable
117440 USD
CY2019Q4 trov Patentlicenseandotherfeespayable
Patentlicenseandotherfeespayable
69950 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66100 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46905 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3850763 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3260061 USD
CY2020 trov Lessee Operating Lease Monthly Rent Payment
LesseeOperatingLeaseMonthlyRentPayment
78000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343001 USD
CY2020 trov Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
CY2020 trov Lessor Number Of Subleases
LessorNumberOfSubleases
3
CY2020 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34169 USD
CY2019 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
441529 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
444878 USD
CY2020 us-gaap Sublease Income
SubleaseIncome
291173 USD
CY2019 us-gaap Sublease Income
SubleaseIncome
381653 USD
CY2020 us-gaap Lease Cost
LeaseCost
150356 USD
CY2019 us-gaap Lease Cost
LeaseCost
63225 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697418 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
860206 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
865379 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9291 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860963 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
869497 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1726342 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
943959 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
916762 USD
CY2018Q4 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
8.91
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
889586 USD
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
403345 USD
CY2020Q4 trov Lessee Operating Lease Liability Payments Net Of Sublease Income Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths
486241 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5868 USD
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
0 USD
CY2020Q4 trov Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
5868 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3423 USD
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
0 USD
CY2020Q4 trov Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
3423 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
898877 USD
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
403345 USD
CY2020Q4 trov Lessee Operating Lease Liability Payments Net Of Sublease Income Due
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
495532 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
29380 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
869497 USD
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3649341 shares
CY2018 trov Warrants Weighted Average Contractual Term
WarrantsWeightedAverageContractualTerm
P4Y4M24D
CY2019 trov Class Of Warrant Or Right Number Granted
ClassOfWarrantOrRightNumberGranted
7437454 shares
CY2019Q4 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
4.08
CY2019 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
1.87
CY2019 trov Class Of Warrant Or Right Number Exercised
ClassOfWarrantOrRightNumberExercised
497313 shares
CY2019 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
6.60
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10589482 shares
CY2019 trov Warrants Weighted Average Contractual Term
WarrantsWeightedAverageContractualTerm
P3Y8M12D
CY2020 trov Class Of Warrant Or Right Number Granted
ClassOfWarrantOrRightNumberGranted
5831451 shares
CY2020 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
1.70
CY2020 trov Class Of Warrant Or Right Number Exercised
ClassOfWarrantOrRightNumberExercised
11159941 shares
CY2020 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
2.31
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5260992 shares
CY2020Q4 trov Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.19
CY2020 trov Warrants Weighted Average Contractual Term
WarrantsWeightedAverageContractualTerm
P4Y1M6D
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2019Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
333333 shares
CY2019Q1 trov Servicereceivable
Servicereceivable
1675000 USD
CY2020Q2 trov Class Of Warrant Or Right Months Until Exercisable
ClassOfWarrantOrRightMonthsUntilExercisable
P6M
CY2020Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1546700 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2213115 shares
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
863852 shares
CY2020Q2 trov Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
2700000 USD
CY2020Q2 trov Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
184426 shares
CY2020Q2 trov Class Of Warrant Or Right Months Until Exercisable
ClassOfWarrantOrRightMonthsUntilExercisable
P6M
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.05
CY2020Q2 trov Class Of Warrant Or Right Expiration Term
ClassOfWarrantOrRightExpirationTerm
P5Y6M
CY2020Q2 trov Warrants Fair Value
WarrantsFairValue
370666 USD
CY2020Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
800000 shares
CY2020Q1 trov Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
1000000.0 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
904970 shares
CY2020Q2 trov Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
1100000 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
447761 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.34
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
146854 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.43
CY2020Q2 trov Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
810000 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1205400 shares
CY2020Q2 trov Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
2500000 USD
CY2020Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6500000 shares
CY2020Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.50
CY2020Q4 trov Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
100900000 USD
CY2020Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
94000000.0 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1764804 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
884943 USD
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1522984 USD
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
386654 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-4043000 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2634000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-92000 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-148000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4135000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2782000 USD
CY2020Q4 trov Valuation Allowance
ValuationAllowance
4134000 USD
CY2019Q4 trov Valuation Allowance
ValuationAllowance
2781000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4054000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3447000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-122000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-177000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2020 trov Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
261000 USD
CY2020 trov Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2019 trov Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
353000 USD
CY2019 trov Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
81000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
875000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.05
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
300000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.02
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
384000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.02
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4134000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.22
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2780000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.17
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42331000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38494000 USD
CY2020Q4 trov Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
3904000 USD
CY2019Q4 trov Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
3710000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
684000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
531000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1116000 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1252000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
48035000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43987000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
74000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
154000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
12000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
80000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
166000 USD
CY2020Q4 trov Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
47955000 USD
CY2019Q4 trov Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
43821000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47955000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43821000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD

Files In Submission

Name View Source Status
0001628280-21-003277-index-headers.html Edgar Link pending
0001628280-21-003277-index.html Edgar Link pending
0001628280-21-003277.txt Edgar Link pending
0001628280-21-003277-xbrl.zip Edgar Link pending
a1016ex022521.htm Edgar Link pending
a1017ex022321.htm Edgar Link pending
a109ex022521.htm Edgar Link pending
a231exq42020.htm Edgar Link pending
a311exq42020.htm Edgar Link pending
a312exq42020.htm Edgar Link pending
a321exq42020.htm Edgar Link pending
a322exq42020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trov-20201231.htm Edgar Link pending
trov-20201231.xsd Edgar Link pending
trov-20201231_cal.xml Edgar Link unprocessable
trov-20201231_def.xml Edgar Link unprocessable
trov-20201231_htm.xml Edgar Link completed
trov-20201231_lab.xml Edgar Link unprocessable
trov-20201231_pre.xml Edgar Link unprocessable